Two-site binding enzyme immunoassay for pregnancy-specific -1 glycoprotein (SP1) has been developed using two monoclonal antibodies which can recognize all the three forms of SP1 from human sera. This assay system detects a minimal concentration of 1.25 ng/ml, and shows a linear dose-response curve at a range between 1.4 and 45.0 ng/ml. The recovery rates ranged from 90.0% to 113.3%, and intra-assay coefficients of variation were 15.8% and 8.7% for two different samples. When compared with a commercial EIA kit, this assay system had high correlation coefficient (r = 0.92) but with somewhat lower values. K e y w o r d s ; enzyme immunoassay, monoclonal antibody, pregnancy-specific β-1 glycoprotein (SP1)
Introduction
Human pregnancy-specific β-1 glycoproteins (Schwangerschafts-protein 1, SP1) are a group of closely related placental glycoproteins and members of the immunoglobulin superfamily (Plouzek and Chou, 1991) . Originally, they were discovered independently by Tatarinov and Masyukevich (1970) and Bohn (1971) as one of the pregnancy-specific proteins. These proteins can be produced in human intestinal tissue (Shupert and Chan, 1993) , T lymphocytes (Wu et al., 1993) and male reproductive tract (Richardson et al., 1991) . However, they are mainly synthesized in the syncytiotrophoblast of placenta (Heikinheimo et al., 1981) and secreted into the maternal circulation in increasing amounts as gestation progresses (Braunstein et al., 1980) , reaching a maximum of about 0.2 mg/ml in the 34th week of gestation (Bohn, 1972) . In males and nonpregnant females, circulating levels of the protein are less than 3 ng/ml (Searle et al., 1978) . The function of the protein is still unknown, although some studies have indicated an immunosuppressive role during pregnancy (Cerni et al., 1977) .
Clinical studies indicate that the measurement of SP1 may be useful for determining complications of early pregnancy such as threatened abortion (Sterzik et al., 1986) and ectopic pregnancy (Seppala et al., 1980) , and as a marker for monitoring the treatment of choriocarcinoma (Searle et al., 1978) and germ cell tumors (Rosen et al., 1979; Englund et al., 1991) . In addition, many tumors including breast (Wurz et al., 1979) , colorectal (Haynes et al., 1985) and lung (Grudzinskas et al., 1980; Boucher and Yoneda, 1995) cancers have been reported to produce SP1. However, many reports on the correlation of serum SP1 level with various clinical conditions show considerable discrepancies from reports to reports in each cancer. This may partly be due to differences in the immunological reagents and techniques used for the detection of SP1 (Engvall et al., 1982) .
Many studies suggest strongly that SP1 has a heterogeneous nature (Sorensen, 1982; Chan and Qiu, 1988; Kahn et al., 1989) , mainly reveals 3 bands (72, 64 and 54 kDa) on SDS electropherogram (Mueller et al., 1985; Plouzek and Chou, 1991) , and has at least 3 different cDNAs (Kahn et al., 1989) . Therefore, when different batches of polyclonal antisera were used, assays would yield variable results. However, monoclonal antibodies are expected to give reproducible results because of their highly specific and uniform nature. In our previous report (Lee et al., 1991) , we reported production of SP1-specific monoclonal antibodies. The development of two-site binding enzyme immunoassay system for SP1 is described in the present paper. 
Materials and Methods

Iodogen
Preparation of monoclonal antibodies
Hybridoma cell lines established in our previous work (Lee et al., 1991) were cultured in DMEM containing 10% fetal bovine serum, 100 mM hypoxanthine, 16 mM thymidine and gentamycin (50 µg/ml). Ascitic fluids were produced by inoculation of cultured hybridoma cells into the peritoneal cavities of incomplete Freund's adjuvant pre-treated Balb/c mouse (Mueller et al., 1986) . Monoclonal antibodies were precipitated from the ascitic fluids by 50%saturation of ammonium sulfate, followed by dialysis against PBS. After clarification of the dialyzed sample by centrifugation, the sample was applied to a protein A-sepharose column previously equilibrated with Immunopure binding buffer ( Pierce). Bound antibodies were eluted by using Immunopure elution buffer ( Pierce).
Immunoprecipitation
Partially purified SP1 (Lee et al., 1991) was radiolabelled with 1 2 5 I using Iodogen (Pierce) according to the manufacturer's instruction. Monoclonal antibodies to SP1 were covalently cross-linked to CNBr-activated Sepharose 4B (Pharmacia) according to the manufacturer's instruction. The radioiodinated SP1 (7.5 x 10 6 cpm/tube) was incubated with irrelevant mouse antibody-linked Sepharose 4B beads at room temperature for 1 h, followed by centrifugation. The same procedure was repeated for the supernatant. Then, the supernatant was incubated with anti-SP1 monoclonal antibody-linked Sepharose 4B beads at room temperature for 12 h. After decanting the supernatant, the precipitated beads were washed with PBS containing 0.05% Tween-20 until the radioactivity of the wash-out solution became negligible. The beads were incubated with SDS-PAGE sample buffer at 90˚C for 3 min, and the supernatants were subjected to SDS-PAGE. The gel was dried and autoradiographed at -70˚C.
Horseradish peroxidase (HRP)-conjugation
The purified antibodies were conjugated with HRP according to the method of Nakane and Kawaoi (1974) . Briefly, amino groups on HRP molecules were blocked with 1-fluoro-2,4-dinitrobenzene, and subsequently HRP was oxidized with sodium periodate to formylate its sugar moiety. After the removal of the remaining sodium periodate by dialysis, the monoclonal antibody solution was added to HRP-aldehyde solution. The conjugate was separated from free HRP by gel filtration on a Sephadex G-200 column. Fractions were collected and their absorbances were measured at 280 nm for protein and 405 nm for HRP heme group.
Preparation of SP1 standards and "zero control serum"
SP1 standards in Enzygnost™ kit (Behring, Germany) were used for this study. Zero control serum was prepared by diluting the sera which contain less than 0.3 ng/ml SP1, when measured by Enzygnost™ EIA kit, to 1:5 with PBS containing 1% BSA.
Two-site binding enzyme immunoassay
Polystyrene tubes were used instead of ELISA plate. The tubes were coated with a monoclonal antibody (SP106-1-12) in 50 mM sodium bicarbonate buffer, pH 9.6 (15 µg/ml) by incubating at 4˚C overnight. After blocking remaining sites with 1% (w/v) bovine serum albumin, SP1 standards or samples (200 µl) were added to each tube. After incubation at 37˚C for 2 h, the tubes were washed three times with distilled water. Then, 200 µl of HRP-labelled antibody solution(1.5 µg/ml SP119-4-1 antibody in PBS containing 1% BSA) was added to each tube. Incubation was carried out at 37˚C for 2 h, and the tubes were then washed three times with distilled water. Subsequently, 200 µl of the substrate solution (100 mM citrate buffer, pH 5.0, containing 2 mg/ml o -phenylene diamine and 0.005% H 2 O 2 ) was added, the tubes were incubated at room temperature for 25 min, and then 400 µl of 0.5 N H 2 SO 4 solution was added to each tube to stop the enzyme reaction. Absorbance of the solution was measured at 492 nm.
Results
Of the eight monoclonal antibodies against SP1 which we produced (Table 1) , SP106-1-12 was selected as a capture antibody and SP119-4-1 as a labelled antibody, because this combination showed relatively high sensitivity with low non-specific binding (data not shown) for measuring three isoforms of SP1 from pregnant serum (Figure 1) . The molecular mass of the three isoforms were 68, 64 and 56 kDa, respectively.
A typical dose-response curve is shown in Figure 2 . It shows a linear dose-response relationship at the concentration range of 1.4-45.0 ng/ml. The "high-dose hook effect" was observed in the concentrations above 10 µg/ml (Figure 3) . However, up to the level of 200 µg/ml, the absorbance of the samples was much higher than that of the sample containing 45.0 ng/ml SP1, which was the highest concentration of the standards.
As shown in Table 2 , the lower limit of detection was estimated to be 1.25 ng/ml. The lower limit of detection was defined as that concentration of SP1 which this assay system can show statistically significant difference from the "zero control serum".
Intra-assay variation is assessed by measuring two serum samples with different amounts of SP1. As 
Discussion
Of the eight monoclonal antibodies produced against SP1, three antibodies were shown by immunoprecipitation reaction to recognize all the three different isoforms of SP1 in serum (Figure 1) . In order to measure all forms of SP1, these three antibodies were chosen in the present assay system. Every possible combinations employing three antibodies as capture antibodies or labelled antibodies were tried. Ho w e v e r , the assay system using SP106-1-12 as a capture antibody and SP119-4-1 as a labelled antibody was chosen, because this combination showed relatively high sensitivity with low non-specific binding for measuring SP1.
A typical standard curve shows that our assay system has a linear dose-response relationship in the concentration range between 1.4 and 45 ng/ml. It is comparable with Enzygnost™ EIA system (3 to 300 ng/ml). In immunoradiometric assays, a paradoxical reversal of the dose-response relation, so called "hook effect", often emerges at a high concentration range (Janina et al., 1979) . This can sometimes be eliminated by using sequential rather than simultaneous application of different antibodies (Chard, 1987) . Although two antibodies were used sequentially in this study, "hook effect" was still observed above the concentration of 10 µg/ml. However, even when we measure serum samples with as high as about 200 µg/ml SP1, the signal still remains far higher than that of the sample containing 45 ng/ml SP1, which is the highest concentration among the standards. Therefore, practically none of the samples within the range of "hook effect" can be underestimated, since investigators will always dilute them to measure correct amount of SP1.
The lower limit of detection of this assay method was 1.25 ng/ml. This value is much higher than the lower 184 Exp. Mol. Med. shown in Table 3 , the intra-assay coefficients of variation were 15.8% for sample 1 (1.25 ng/ml) and 8.7% for sample 2 (14.4 ng/ml). The recovery of the assay was assessed by adding aliquots of serum with a high SP1 concentration to a serum with a low SP1 concentration. The SP1 concentrations were measured and compared with estimated concentrations. The recoveries ranged from 90.0% to 113.3% (Table 4) . When compared with the Enzygnost ™ EIA kit, this limit of detection by Enzygnost™ EIA kit (Behring), but is still lower than the one reported in a previous study using their monoclonal antibodies (Engvall et al., 1982) . Also, the cut-off value for deciding pregnancy is 2 (Pak et al ., 1988) or 3 ng/ml (insert manual of Enzygnost™ EIA kit) which are higher than the lower limit of detection of our assay system. The intraassay coefficients of variation of our system were 15.8% for sample 1 (1.25 ng/ml) and 8.7% for sample 2 (14.4 ng/ml). These values were somewhat higher than those reported by Alexander (1981) (2.6%) and Macdonald et al. (1979) (6.5, 7.4%) . When compared with Enzygnost™ EIA kit, our assay system showed a high correlation coefficient, but has a tendency to have lower value. This may be due to the differences in reactivity of polyclonal and monoclonal antibodies toward different forms of SP1.
In conclusion, it is not certain which system is better in terms of accuracy. However the assay system using monoclonal antibodies should be more consistent in assay than those using polyclonal antibodies, because they do not have batch variations.
